Sen. Kennedy Death Puts Focus On Brain Cancer
Glioblastoma multiforme (GBM), the aggressive brain tumor that took Sen. Kennedy’s life, is one of the deadliest brain tumors that can occur in both adults and children.
Profiles
NeoPharm Tipped As Stock to Watch
NeoPharm, a biopharmaceutical company developing drugs for cancer treatment, has been tipped as a worthwhile stock on financial website Seeking Alpha.
BioNeutral Ygiene Kills Swine Flu in 20 Seconds, Test Shows
BioNeutral of Newark, NJ, announced that its Ygiene Consumer Grade antimicrobial formulation swiftly eradicated the H1N1 swine flu virus in an independent lab test.
SyntheMed REPEL-CV Receives Russian Approval
SyntheMed announced that its REPEL-CV barrier has received approval from the Ministry of Health of the Russian Federation for use in all patients who undergo open heart surgery.
OneMedPlace Interviews Jeffrey Davis, CEO of Access Pharmaceuticals
OneMedPlace recently sat down with Jeffrey Davis, CEO of Access Pharmaceuticals, to discuss the clinical success of MuGard and the latest news surrounding the product’s launch.
SyntheMed Receives Endorsement, New Patent
REPEL-CV, a bioresorbable anti-adhesion barrier developed by biomaterials company SyntheMed, has received an endorsement from Kids with Heart.
Independent Study Validates BioNeutral’s Ygiene
In an independent study, BioNeutral’s Ygiene antimicrobial formulation eliminated a particularly dangerous type of mold in record time.
Positive Peer Review for Aureon’s Prostate Px+
The peer reviewed results published today in the Journal of Urology found that Aureon Laboratories’ Prostate Px+ test is twice as effective as other tools currently available at identifying which patients classified as intermediate-risk have high-risk, life-threatening cancer.
Aureon Featured In TV Segment
Aureon Laboratories, a developer of predictive tests for cancer care, has been featured in a cable television segment produced by the Yonkers Chamber of Commerce.
Clarient Files Registration Agreement With SEC
Clarient has filed a registration statement with the Securities and Exchange Commission on Form S-3 relating to shares of Clarient owned by Safeguard.